Scienza e Tecnologia
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal disorders
"The new patent enables the company to develop and commercialize naronapride for multiple gastrointestinal disorders requiring a prokinetic over the next two decades in order to establish it as a potential best-in-class prokinetic." said Peter Milner M.D ., FACC, Chairman and CEO.
No safe and effective GI motility agent is currently available to patients. The last such agents approved were cisapride (Propulsid®) and tegaserod (Zelnorm®), which each sold over $1Bn annually and were withdrawn over 10 years ago due to cardiac safety concerns.
Naronapride is a late-phase clinical stage drug candidate which possesses a unique combination of both 5HT4 agonistic and D2 antagonistic properties and works in both upper and lower GI. It is locally active in gut lumen, designed to be minimally absorbable, side-effect profile indistinguishable from placebo. Four positive Phase 2 studies completed in upper and lower GI indications and is Phase 3 ready in CIC (chronic idiopathic constipation) and GERD (gastro-esophageal reflux). Naronapride was engineered to avoid any cardiac safety risk. Its oral formulation serves large unmet needs in CIC, IBS-c, PPI-resistant GERD and gastroparesis.
Renexxion Ireland Ltd. is a privately held biopharmaceutical company committed to delivering new drugs to patients with GI motility disorders with its operations and drug development team based in Ireland . For more information, refer to http://www.rnexltd.ie.
Catherine Pearson , Chief Operating Officer, at Press@rnexltd.ie, or on +353 61 539121